Polyunsaturated Fatty Acids for Treatment of Dementia and Pre-Dementia-Related Conditions

• US 20110218242A1
• Filed: 03/04/2011
• Published: 09/08/2011
• Est. Priority Date: 07/08/2005
• Status: Abandoned Application

• Current Assignee: DSM IP Assets BV (DSM-Firmenich AG)
• Original Assignee: DSM IP Assets BV (DSM-Firmenich AG)
• Inventors: ELLIS, Lorie A.
• Application Number:
  US13/041,279
• Publication Number:
  US 20110218242A1
• Time in Patent Office: Days
• US Class Current: 514/547
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions.

Claims

1-63. -63. (canceled)

64. A method of treating a human with age-related cognitive decline, comprising:

administering to a human in need thereof a therapeutically effective amount of an oral dosage formulation comprising docosahexaenoic acid (DHA) and docosapentaenoic acid n-6 (DPAn-6), wherein the DHA and DPAn-6 are in a ratio from about 1;

1 to about 10;

1.

65. The method as recited in claim 64, wherein the DHA is administered in an amount from about 50 mg per day to about 20 grams per day.

66. The method as recited in claim 64, wherein the DHA and DPAn-6 are in a ratio of about 2.5:

1.

67. The method as recited in claim 64, wherein the oral dosage formulation comprises an oil or formulation comprising about 40% or more by weight of a combination of DHA and DPAn-6.

68. The method as recited in claim 64, wherein the oral dosage formulation comprises an oil or formulation comprising about 50% or more by weight of a combination of DHA and DPAn-6.

69. The method as recited in claim 64, wherein oral dosage formulation comprises an oil or formulation comprising about 60% or more by weight of a combination of DHA and DPAn-6.

70. The method as recited in claim 64, wherein the oral dosage formulation comprises an oil or formulation comprising about 70% or more by weight of a combination of DHA and DPAn-6.

71. The method as recited in claim 64, wherein oral dosage formulation comprises an oil or formulation comprising about 80% or more by weight of a combination of DHA and DPAn-6.

72. The method as recited in claim 64, wherein the DHA is in the form of a triglyceride oil.

73. The method as recited in claim 64, wherein the DHA is in the form of an ester.

74. A method of treating a human with age-related cognitive decline, comprising:

administering to a human in need thereof a therapeutically effective amount of an oral dosage formulation comprising docosahexaenoic acid (DHA), wherein the formulation comprises eicosapentaenoic acid (EPA) in an amount of about 1.36% or less as a percentage of total fatty acids.

75. The method as recited in claim 74, wherein the DHA is administered in an amount from about 50 mg per day to about 20 grams per day.

76. The method as recited in claim 74, wherein the oral dosage formulation comprises an oil or formulation comprising about 40% or more by weight of DHA.

77. The method as recited in claim 74, wherein the oral dosage formulation comprises an oil or formulation comprising about 50% or more by weight of DHA.

78. The method as recited in claim 74, wherein the oral dosage formulation comprises an oil or formulation comprising about 60% or more by weight of DHA.

79. The method as recited in claim 74, wherein oral dosage formulation comprises an oil or formulation comprising about 70% or more by weight of DHA.

80. The method as recited in claim 74, wherein the oral dosage formulation comprises an oil or formulation comprising about 80% or more by weight of DHA.

81. The method as recited in claim 74, wherein the DHA is in the form of a triglyceride oil.

82. The method as recited in claim 74, wherein the DHA is in the form of an ester.

83. The method as recited in any of claims 74-82, wherein the oral dosage formulation comprises no EPA.

84. The method as recited in any of claims 74-82, wherein the oral dosage formulation comprises arachidonic acid (ARA) in an amount of about 0.52% or less as a percentage of total fatty acids.

85. The method as recited in any of claims 74-82, wherein the oral dosage form comprises no arachidonic acid (ARA).

86. The method as recited in any of claims 74-82, wherein the oral dosage form comprises no EPA and no arachidonic acid (ARA).

87. A method of treating a human with age related cognitive decline, comprising:

administering to a human in need thereof an oral dosage formulation comprising 40% or more by weight of DHA, wherein the DHA is administered in an amount from about 50 mg per day to about 20 grams per day.

88. The method as recited in claim 87, wherein the DHA is in the form of a triglyceride oil.

89. The method as recited in claim 88, wherein the DHA is in the form of an ester.